Work with thought leaders and academic experts in Cancer Research

Companies can greatly benefit from working with experts in the field of Cancer Research. These researchers bring a deep understanding of the disease and its mechanisms, allowing them to contribute valuable insights and expertise. Here are some ways companies can collaborate with academic researchers in Cancer Research: 1. Drug Discovery and Development: Academic researchers can assist in the discovery and development of new cancer drugs, providing expertise in target identification, preclinical testing, and clinical trials. 2. Biomarker Identification: Researchers can help identify biomarkers that can be used for early cancer detection, patient stratification, and monitoring treatment response. 3. Genomic Analysis: Experts in Cancer Research can analyze genomic data to identify genetic mutations and variations associated with cancer, enabling personalized treatment approaches. 4. Translational Research: Collaboration with academic researchers can facilitate the translation of basic research findings into clinical applications, bridging the gap between bench and bedside. 5. Clinical Trials: Companies can partner with academic researchers to conduct clinical trials, leveraging their expertise in trial design, patient recruitment, and data analysis. 6. Data Analytics: Researchers can apply advanced data analytics techniques to large-scale cancer datasets, uncovering patterns and insights that can inform treatment strategies. 7. Collaborative Research Projects: Joint research projects between companies and academic researchers can lead to innovative solutions and breakthrough discoveries in cancer treatment and prevention. 8. Education and Training: Academic researchers can provide educational programs and training to company employees, keeping them updated on the latest advancements in Cancer Research. 9. Intellectual Property: Collaboration with academic researchers can result in the generation of intellectual property, including patents and publications, which can enhance a company's competitive advantage. 10. Access to Networks and Resources: Academic researchers have access to extensive networks and resources, including collaborations with other experts, funding opportunities, and state-of-the-art facilities.

Researchers on NotedSource with backgrounds in Cancer Research include Ramy Ayoub, Gwendolyn Thomas, Ph.D., CSCS, USAW-L1, Dr. Michael W. Craige, PhD, MBA, Elvira Forte, Dr. Lindsey Kuehm, Ph.D., Ping Luo, John M Baust, Ph.D, Elena Shersher, Ph.D., Dr. Everson A Nunes, Ph.D., Dr. Shilpa Patil, Ph.D, and Boris Leibovitch.

Ramy Ayoub

Toronto, Ontario, Canada
5 Years Experience
PhD Medical Biophysics
Education

University of Toronto

Ph.D., Medical Biophysics / October, 2023 (anticipated)

Toronto, Ontario, Canada
Experience

The Hospital for Sick Children

PhD Scientific Researcher / September, 2018 — October, 2023

Designed strategies to limit negative complications experienced by brain tumour survivors treated with radiation; Conducted genetic and pharmacological interventions in mouse models to determine translatability of strategies; Assessed the efficacy of treatment strategies using multi-modal imaging approaches (MRI, serial two-photon imaging); Published findings in peer-reviewed journals Nature, and Radiation Research

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (10)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
Radiology, Nuclear Medicine and imaging
And 5 more
About
Ramy Ayoub obtained his Ph.D. in Medical Biophysics from the University of Toronto in 2023, where he developed a strong foundation in the principles and applications in neuroscience, statistics, machine learning, imaging & radiation physics. During his time at the University of Toronto, Ramy has been involved in conducting cutting-edge research in the field, with a focus on developing new technologies and pharmacological interventions to improve healthcare outcomes. He is passionate about using his skills and expertise to make a positive impact in the medical field and is dedicated to advancing the field through his ongoing research and contributions.
Most Relevant Publications (2+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

See Full Profile

Gwendolyn Thomas, Ph.D., CSCS, USAW-L1

Philadelphia, Pennsylvania, United States of America
17 Years Experience
Resistance Exercise Physiologist/Performance Enhancement/Optimizing RE Prescription
Education

University of Connecticut

Ph.D., Kinesiology (Exercise Endocrinology, Exercise Physiology, Resistance Exercise) / May, 2010

Storrs, Connecticut, United States of America

University of Connecticut

M.A., Strength and Conditioning / May, 2007

Storrs, Connecticut, United States of America
Experience

Penn State University

Assistant Research Professor / September, 2019 — August, 2023

Principal Investigator of the Exercise Prescription Lab. The lab (PI: Thomas) conducts interdisciplinary and translational research on chronic diseases, publishing in peer-reviewed journals. Transform population health outcomes through data, analytics, and actionable insights. Chair the regulatory review board, overseeing IRB Administration, running meetings, and approving research protocols. Expertise in institutional, FDA, and Federal regulatory work.

Penn State Integrative Physiology

Faculty Member / September, 2019 — Present

Faculty Member In Integrative Physiology

Syracuse University

Assistant Professor / August, 2016 — August, 2019

Independent Principal Investigator: Assumed responsibility for all research studies conducted in my lab, including but not limited to oversight and training of research assistants (25), training of research assistants (30), and generating independent, high quality, reproducible results. Responsible for the management and integrity of design, conduct and reporting of the research project and for managing, monitoring and ensuring the integrity of collaborative relationships. Curriculum Committee Chair:Led Curriculum Committee and Departmental Leadership to develop Master’s Degree in Strength and Conditioning through certifying agency, the National Strength and Conditioning Association (NSCA).

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (30)
resistance exercise
obesity
breast cancer
chronic disease
inflammation
And 25 more
About
My work has focused on how we can use data to support decisions to individualize monitoring to optimize human performance.  My work has demonstrated that a one size fits all approach is not the way to optimize performance in any setting.  My monitoring approach is one that utilizes a network physiology paradigm, which focuses on nonlinear dynamic interactions. In my athlete monitoring I focus on leveraging EMA and wearables; biological sampling and resistance exercise and conditioning prescribed to elicit a specific biological response.    Additionally, as a practitioner it is important to understand the limitations of athlete monitoring, which is another area research and practice has focused.  This is an important skillset that is currently being utilized by the in a project entitled “Integrating mHealth and Physical Function to Develop a Predictors of Injury and Optimal Performance Model in Special Military Operators “with the Rangers in the 3/75 Ranger Battalion.  This approach is one that quantifies factors such as dosage variables of training and lifestyle factors (sleep, nutrition, life stress).  Using this data, we are working on individualizing acute training sessions to optimize readiness and performance enhancement.   During my time at Syracuse University, I was the professor of record to teach the NSCA CSCS preparation course and lead the strength and conditioning program.  We were developing a master’s in exercise science and I was in the process of working on certification with the NSCA.  We also worked closely with athletics to secure strength and conditioning assistantships to allow for student funding.  I am currently on several NSCA committees, which include the Education and Women’s Committee (next certification cycle).    I am particularly adept at all phases of the athletic performance enhancement and these experiences have given me expertise in evidence based program design, linear and non-linear periodization, exercise endocrinology, resistance exercise physiology and acute and chronic training readiness and non-training parameters
Most Relevant Publications (4+)

51 total publications

Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation

BMC Cancer / Jan 22, 2019

van Rooijen, S., Carli, F., Dalton, S., Thomas, G., Bojesen, R., Le Guen, M., Barizien, N., Awasthi, R., Minnella, E., Beijer, S., Martínez-Palli, G., van Lieshout, R., Gögenur, I., Feo, C., Johansen, C., Scheede-Bergdahl, C., Roumen, R., Schep, G., & Slooter, G. (2019). Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer, 19(1). https://doi.org/10.1186/s12885-018-5232-6

Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study

Cancer Prevention Research / Feb 01, 2013

Jones, S. B., Thomas, G. A., Hesselsweet, S. D., Alvarez-Reeves, M., Yu, H., & Irwin, M. L. (2013). Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study. Cancer Prevention Research, 6(2), 109–118. https://doi.org/10.1158/1940-6207.capr-12-0278

Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis

Cancers / Jul 25, 2023

Giles, E. D., Purcell, S. A., Olson, J., Vrieling, A., Hirko, K. A., Woodruff, K., Playdon, M. C., Thomas, G. A., Gilmore, L. A., Moberly, H. K., & Newell-Fugate, A. E. (2023). Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis. Cancers, 15(15), 3761. https://doi.org/10.3390/cancers15153761

Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities

JNCI Monographs / May 04, 2023

Gilmore, L. A., Parry, T. L., Thomas, G. A., & Khamoui, A. V. (2023). Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities. JNCI Monographs, 2023(61), 30–42. https://doi.org/10.1093/jncimonographs/lgad006

See Full Profile

Dr. Michael W. Craige, PhD, MBA

New York
18 Years Experience
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Education

Rutgers, The State University of New Jersey

Ph.D., Biomedical Informatics

New Brunswick, New Jersey, United States of America

Georgia Tech

MBA, Business Administration and Management

Atlanta, Georgia, United States of America

DeVry University

Master on Health Service/Management, Healthcare Administration

Downers Grove, Illinois, United States of America
Experience

CiDrep Informatics

CEO / January, 2012 — December, 2020

Biomedical Informatics • Research Technology • Informatics • Cancer Data Science • Clinical Data Management

Rutgers, The State University of New Jersey

Postdoctoral Research Fellow / August, 2021 — April, 2024

Oncology Data Science (Prostate Cancer)

Emory University School of Medicine

Scientist / March, 2020 — July, 2021

Pediatric Neurology (Epilepsy)

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (5)
Biomedical Informatics
Computational Biology
Neuroinformatics
Bioinformatics
Oncology
About
Dr. Michael W. Craige is a research scientist and fellow, leveraging his expertise in biomedical informatics, data science, intellectual property law, and innovation strategy to assess patent, and license new inventions and technologies reported by scientists. He has contributed to publications in high-impact journals, such as Nature Communications and Frontiers in Oncology, and has helped several startups secure their first institutional venture capital funding. His professional journey encompasses a rich blend of roles, including an NSF I-Corps Startup Mentor at Rutgers Office of Innovation Ventures, his recent tenure as a Venture Capital Fellow at SOSV's IndieBio in New York, and training in intellectual property law as a patent agent at Casimir Jones Law Firm. Dr. Craige received his MBA from The Georgia Institute of Technology and his PhD in Biomedical Informatics at Rutgers University where he’s developing computational methods for high-throughput cancer genomic data analysis, including statistical models for elucidating the mechanisms of prostate cancer disease progression and therapeutic response. During his doctoral program, he focused his research on pediatric neurology to understand the underline molecular mechanism of epilepsy in infants, jointly at Emory and Rutgers University. Dr. Craige was the managing director and ex-founder at CiDrep Informatics, a health and scientific-informatics consulting firm, that operated across the US and Canada.
Most Relevant Publications (1+)

3 total publications

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

Frontiers in Oncology / Sep 06, 2023

Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168

See Full Profile

Elvira Forte

New York, New York, United States of America
15 Years Experience
Scientific strategist • Senior Scientist • Senior Scientific Editor
Education

Sapienza University of Rome

PhD, Pasteurian Sciences / January, 2011

Rome

Sapienza University of Rome

Master, Medical, Molecular and Cellular Biotechnology / October, 2006

Rome

Sapienza University of Rome

Bachelor, Biotechnology / October, 2004

Rome
Experience

Springer Nature

Associate/Senior Editor / June, 2021 — February, 2024

Helped shape and launch a new journal, Nature Cardiovascular Research, which publishes exceptional advances in the fields of cardiac, vascular, and blood biology, covering fundamental, translational, clinical, and public health research. • Assessed the novelty and impact of manuscripts within all the topics covered by the journal and chaperoned the whole revision process until acceptance for over 40% of all the content published by the journal since its start, with optimal processing times and excellent feedback from the authors. • Interfaced with scientists around the World, provided scientific guidance on how to improve manuscripts, or recommended more appropriate journals to publish with. Commissioned Comments, Reviews, News and Views on current topics, and summarized novel scientific findings in meaningful snippets and Research Highlights. • Contributed to the training and supervision of 2 Associate Editors; covered the Chief Editor's functions when needed.

Research Fellow/Associate Research Scientist / January, 2017 — June, 2021

• Analyzed the dynamic cellular changes during the fibrotic repair post-myocardial infarction, using cutting-edge techniques such as single-cell RNAseq with 10xChromium. Learned how to perform myocardial infarction in mice and assess the cardiac function via echography; analyze scRNAseq data using the Seurat package on R studio. • Completed a project aimed to characterize similarities and differences among fibroblasts from different organs cultured in the same conditions. Through cytometric, transcriptomic analysis, functional assays, shRNA and CRISPR-Cas9-mediated in vitro gene knockdowns we showed that fibroblasts isolated from different organs retain the expression of key transcription factors reflecting their embryological origin. • Collaborated with other laboratories in the Institute to design new mice models that could possibly recapitulate the symptoms of COVID-19; to analyze the response of mice with diverse genetic backgrounds to stressors.

Post-doctoral fellow/ Co-joint lecturer / May, 2013 — November, 2016

Developed projects aimed at understanding the embryological origin and function of a population of putative progenitor cells, cardiac colony forming unit fibroblasts cCFU-F, identified 2 years before in the lab (PMID: 22136928). • Performed cell lineage tracing and designed in vitro and in vivo cellular assays to assess the functional and immunomodulatory properties of PDGFRa+ fibroblasts in homeostasis and post-myocardial infarction with or without treatment with the PDGF-AB ligands. The data, presented in 3 international conferences and included in a preprint manuscript, have supported the use of a short-term treatment with PDGF-AB in a preclinical model of acute myocardial infarction in pigs. • Co-supervised 2 Ph.D. students at University of New South Wales

Scientific Editor / March, 2024 — Present

Consultant freelancer position within a team of former journal editors and grants specialists • Helped scientists increase the impact of their science by providing advice, in-depth editing, and feedback on manuscripts.

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (26)
fibrosis
inflammation
cardiomyopathies
Physiology
Cardiology and Cardiovascular Medicine
And 21 more
About
Motivated and growth-driven biomedical scientist with over 15 years of experience in the cardiovascular field. Strong background in cell and molecular biology, data analysis, and interpretation. Seeking #newopportunities to deliver value as a Senior Scientist, Associate Principal Scientist, Scientific Liaison, or Scientific Consultant within a company that combines new technologies such as single-cell omics and AI for drug discovery and personalized medicine. <br> Throughout my career, I've used various in vivo and in vitro models to investigate the molecular and cellular mechanisms of fibrosis and inflammation in the heart, and how these mechanisms are affected in mice with different genetic backgrounds. My experience includes project management and mentoring. I completed three projects involving international collaborations, supervised two junior researchers, and taught cellular and molecular techniques to at least six professionals. As one of the launching editors and senior editor at Nature Cardiovascular Research, I oversaw the quality of the content published in the journal and the editorial process. I collaborated with authors, reviewers, and editors to ensure the highest standards of scientific rigor, relevance, and innovation. I also contributed to the journal's vision, strategy, and outreach, promoting the latest advances and discoveries in the cardiovascular and hematology fields. This experience has sharpened my analytical and communication skills and broadened my understanding of the field, covering a wide range of studies, from basic research to clinical, epidemiological, and public health research. My mission is to advance the knowledge and practice of cardiovascular medicine and to bridge the gap between research and clinical applications. Keywords: cardiovascular, #fibrosis, inflammation, cardioimmunology, RNA, single-cell biology, #transcriptomics, imaging, animal models, small animal surgery, and scientific writing.
Most Relevant Publications (2+)

63 total publications

EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids

Cancers / Jul 29, 2017

Forte, E., Chimenti, I., Rosa, P., Angelini, F., Pagano, F., Calogero, A., Giacomello, A., & Messina, E. (2017). EMT/MET at the Crossroad of Stemness, Regeneration and Oncogenesis: The Ying-Yang Equilibrium Recapitulated in Cell Spheroids. Cancers, 9(12), 98. https://doi.org/10.3390/cancers9080098

Cardiac Cell Therapy: The Next (Re)Generation

Stem Cell Reviews and Reports / Mar 25, 2011

Forte, E., Chimenti, I., Barile, L., Gaetani, R., Angelini, F., Ionta, V., Messina, E., & Giacomello, A. (2011). Cardiac Cell Therapy: The Next (Re)Generation. Stem Cell Reviews and Reports, 7(4), 1018–1030. https://doi.org/10.1007/s12015-011-9252-8

See Full Profile

Dr. Lindsey Kuehm, Ph.D.

St. Louis, Missouri, United States of America
14 Years Experience
PhD immunologist specializing in cancer immunotherapy
Education

Saint Louis University

PhD, Molecular Microbiology and Immunology / April, 2020

St Louis, Missouri, United States of America

University of North Texas Health Science Center

MS, Microbiology and Immunology / August, 2014

Fort Worth, Texas, United States of America

University of North Texas

BS, Biology / December, 2008

Denton
Experience

Washington University School of Medicine in St. Louis

Postdoctoral Research Scholar / October, 2023 — Present

Cell Microsystems

Field Application Scientist / February, 2022 — February, 2023

TCR Cure Biopharma

Research Scientist / June, 2020 — January, 2022

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (6)
Immunology
Cancer Immunotherapy
CAR-T Cell Therapy
T Cell Biology
Infectious Disease
And 1 more
About
I am passionate about science and bench to beside clinical research with 14 years of immunology and microbiology experience in both academia and industry.  My past research has focused on T cell immunology, CAR-T cells, and checkpoint blockade cancer immunotherapy. I am also very interested in researching immunotherapy for infectious diseases. My experiences have lead to finely tuned presentation skills and I have many years of experience mentoring high schoolers, undergrads, graduate, medical students, and other scientists.

See Full Profile

Ping Luo

Toronto, Ontario, Canada
8 Years Experience
Assistant Professor at Algoma University
Education

University of Saskatchewan

Ph.D., Biomedical Engineering / September, 2019

Saskatoon, Saskatchewan, Canada

Beijing Institute of Technology

M.Eng., Biomedical Engineering / June, 2015

Beijing

Hunan University

B.Eng., Computer Science / June, 2010

Changsha
Experience

Princess Margaret Cancer Centre

Postdoctoral Researcher / November, 2019 — Present

I work in Dr. Trevor Pugh's lab and design cancer diagnosis and treatment strategies by analyze cell-free DNA and single cell sequencing data

Princess Margaret Cancer Centre

Bioinformatics Specialist / September, 2023 — Present

I work in Dr. Tak Mak's lab and study tumor immunology using single cell and TCR sequencing data.

Research Expertise (22)
single-cell genomics
deep learning
complex network analysis
Genetics (clinical)
Genetics
And 17 more
About
8 years of science and engineering experience integrating multi-omics data to identify biomarkers for cancer studies. Seeking to apply data analytics expertise to develop new diagnosis and treatment strategies.

See Full Profile

John M Baust, Ph.D

Ithaca, New York, United States of America
25 Years Experience
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Education

Harvard Medical School

Post Doc

Boston, Massachusetts, United States of America

Binghamton University

Ph.D.

Binghamton, New York, United States of America

Cornell University

BS

Ithaca, New York, United States of America
Experience

Cell Preservation Services (United States)

President

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (16)
Cell Biology
Biotechnology
Biomedical Engineering
Transplantation
Surgery
And 11 more
About
***Proven success in delivering best-in-class services across highly regulated scientific and commercial environments.*** * Resourceful, dynamic, and future-focused professional; equipped with strategic leadership, business, research, and academic expertise with career excellence in conducting in-depth research, leading multi-faceted R&D projects, and developing new products and treatments. * Dedicated, driven self-starter focused on developing innovative life changing technologies and procedures advancing the areas of cancer treatment, regenerative medicine and cell therapy.   * Substantial experience in providing oversight for medical device development, pre-clinical studies, cancer therapy, stem cell preservation, cell therapy, tissue engineering, and organ transplantation, etc. * Astute at establishing solid relationships with stakeholders and industry leaders to drive innovative ideas and lead collaborative efforts in pursuit of accomplishing long-term milestones. * Successful in delivering interactive academic instruction across higher education settings offering captivating lectures on Biology and Entrepreneurship courses in accordance with the organizational mission. * Accredited with authoring, managing, and executing multi-million dollar grants, corporate contracts * Accomplished author of numerous patents and high profile publications to disseminate essential research findings.
Most Relevant Publications (13+)

68 total publications

Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate

Technology in Cancer Research &amp; Treatment / Apr 01, 2007

Baust, J. G., Gage, A. A., Klossner, D., Clarke, D., Miller, R., Cohen, J., Katz, A., Polascik, T., Clarke, H., & Baust, J. M. (2007). Issues Critical to the Successful Application of Cryosurgical Ablation of the Prostate. Technology in Cancer Research &amp; Treatment, 6(2), 97–109. https://doi.org/10.1177/153303460700600206

Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death

Technology in Cancer Research &amp; Treatment / Apr 01, 2007

Clarke, D. M., Robilotto, A. T., Rhee, E., VanBuskirk, R. G., Baust, J. G., Gage, A. A., & Baust, J. M. (2007). Cryoablation of Renal Cancer: Variables Involved in Freezing-Induced Cell Death. Technology in Cancer Research &amp; Treatment, 6(2), 69–79. https://doi.org/10.1177/153303460700600203

Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques

Technology in Cancer Research &amp; Treatment / Apr 01, 2007

Robilotto, A. T., Clarke, D., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2007). Development of a Tissue Engineered Human Prostate Tumor Equivalent for Use in the Evaluation of Cryoablative Techniques. Technology in Cancer Research &amp; Treatment, 6(2), 81–89. https://doi.org/10.1177/153303460700600204

Integrin involvement in freeze resistance of androgen-insensitive prostate cancer

Prostate Cancer and Prostatic Diseases / Jan 12, 2010

Baust, J. G., Klossner, D. P., VanBuskirk, R. G., Gage, A. A., Mouraviev, V., Polascik, T. J., & Baust, J. M. (2010). Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 13(2), 151–161. https://doi.org/10.1038/pcan.2009.59

Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model

Prostate Cancer and Prostatic Diseases / Jan 11, 2011

Santucci, K. L., Snyder, K. K., Baust, J. M., Van Buskirk, R. G., Mouraviev, V., Polascik, T. J., Gage, A. A., & Baust, J. G. (2011). Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. Prostate Cancer and Prostatic Diseases, 14(2), 97–104. https://doi.org/10.1038/pcan.2010.52

Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model

Prostate Cancer and Prostatic Diseases / Dec 11, 2012

Robilotto, A. T., Baust, J. M., Van Buskirk, R. G., Gage, A. A., & Baust, J. G. (2012). Temperature-dependent activation of differential apoptotic pathways during cryoablation in a human prostate cancer model. Prostate Cancer and Prostatic Diseases, 16(1), 41–49. https://doi.org/10.1038/pcan.2012.48

Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue

Prostate Cancer and Prostatic Diseases / Jan 27, 2015

Baust, J. G., Bischof, J. C., Jiang-Hughes, S., Polascik, T. J., Rukstalis, D. B., Gage, A. A., & Baust, J. M. (2015). Re-purposing cryoablation: a combinatorial ‘therapy’ for the destruction of tissue. Prostate Cancer and Prostatic Diseases, 18(2), 87–95. https://doi.org/10.1038/pcan.2014.54

Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation

Technology in Cancer Research &amp; Treatment / Jun 23, 2016

Baumann, K. W., Baust, J. M., Snyder, K. K., Baust, J. G., & Van Buskirk, R. G. (2016). Characterization of Pancreatic Cancer Cell Thermal Response to Heat Ablation or Cryoablation. Technology in Cancer Research &amp; Treatment, 16(4), 393–405. https://doi.org/10.1177/1533034616655658

Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer

Technology in Cancer Research &amp; Treatment / Jul 08, 2016

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2016). Investigation of the Impact of Cell Cycle Stage on Freeze Response Sensitivity of Androgen-Insensitive Prostate Cancer. Technology in Cancer Research &amp; Treatment, 15(4), 609–617. https://doi.org/10.1177/1533034616648059

Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model

Technology in Cancer Research &amp; Treatment / May 17, 2017

Baust, J. M., Robilotto, A., Snyder, K. K., Santucci, K., Stewart, J., Van Buskirk, R., & Baust, J. G. (2017). Assessment of Cryosurgical Device Performance Using a 3D Tissue-Engineered Cancer Model. Technology in Cancer Research &amp; Treatment, 16(6), 900–909. https://doi.org/10.1177/1533034617708960

Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome

Technology in Cancer Research &amp; Treatment / Jan 01, 2018

Baust, J. M., Rabin, Y., Polascik, T. J., Santucci, K. L., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Defeating Cancers’ Adaptive Defensive Strategies Using Thermal Therapies: Examining Cancer’s Therapeutic Resistance, Ablative, and Computational Modeling Strategies as a means for Improving Therapeutic Outcome. Technology in Cancer Research &amp; Treatment, 17, 153303381876220. https://doi.org/10.1177/1533033818762207

Cryoablation: physical and molecular basis with putative immunological consequences

International Journal of Hyperthermia / Nov 29, 2019

Baust, J. G., Snyder, K. K., Santucci, K. L., Robilotto, A. T., Van Buskirk, R. G., & Baust, J. M. (2019). Cryoablation: physical and molecular basis with putative immunological consequences. International Journal of Hyperthermia, 36(sup1), 10–16. https://doi.org/10.1080/02656736.2019.1647355

Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model

Breast Cancer: Basic and Clinical Research / Jan 01, 2020

Snyder, K. K., Van Buskirk, R. G., Baust, J. G., & Baust, J. M. (2020). Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model. Breast Cancer: Basic and Clinical Research, 14, 117822342097236. https://doi.org/10.1177/1178223420972363

See Full Profile

Elena Shersher, Ph.D.

Miami
7 Years Experience
Cancer researcher at University of Miami
Education

Florida International University

Ph.D., Biochemistry / May, 2016

Miami, Florida, United States of America
Experience

University of Miami

Cancer researcher / March, 2017 — Present

I study cell signaling mechanisms to identify the most promising molecular targets for therapeutic intervention in cancer.

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (5)
Molecular Biology
Biochemistry
Cell Biology
Drug discovery
Cancer cell signaling
About
Elena Shersher, Ph.D. is a highly skilled and experienced biochemist with a strong background in cancer research. She received her Ph.D. in Biochemistry from Florida International University in 2016, where she was a recipient of a prestigious Presidential fellowship. After completing her Ph.D., Elena continued her career as a clinical program development lead and coordinator at a CRO. In 2017, Elena joined a cancer research team at the University of Miami as a researcher. In this role, she utilized her expertise in advanced laboratory techniques and data analysis to study the role of specific proteins in cancer cell signaling in order to identify promising molecular targets for therapeutic intervention. Elena's research has been published in several prestigious scientific journals, and she has presented her findings at numerous conferences. In addition to her research, Elena is also passionate about mentoring and teaching the next generation of scientists. She has served as a mentor and advisor to undergraduate and graduate students, helping them develop their research skills and guiding them in their academic and career paths. Elena's dedication and contributions to the field of cancer research have made her a valuable asset to the scientific community. With her expertise and experience, she continues to make significant advancements in understanding and treating cancer, bringing hope to those affected by this devastating disease.
Most Relevant Publications (2+)

4 total publications

Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells

Cancer Research / Apr 05, 2021

Alvarez-Trotta, A., Guerrant, W., Astudillo, L., Lahiry, M., Diluvio, G., Shersher, E., Kaneku, H., Robbins, D. J., Orton, D., & Capobianco, A. J. (2021). Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells. Cancer Research, 81(12), 3347–3357. https://doi.org/10.1158/0008-5472.can-20-3611

A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase

Molecular Therapy - Oncolytics / Mar 01, 2023

Diluvio, G., Kelley, T. T., Lahiry, M., Alvarez-Trotta, A., Kolb, E. M., Shersher, E., Astudillo, L., Kovall, R. A., Schürer, S. C., & Capobianco, A. J. (2023). A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase. Molecular Therapy - Oncolytics, 28, 307–320. https://doi.org/10.1016/j.omto.2023.02.008

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
19 Years Experience
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Education

Universidade Federal do Paraná - Campus Centro Politécnico

PhD, Physiological Sciences / December, 2009

Curitiba

Universidade Federal do Paraná - Campus Centro Politécnico

BSc - Human Nutrition / December, 2007

Curitiba

Universidade Federal do Paraná - Campus Centro Politécnico

MSc, Physiological Sciences / March, 2005

Curitiba
Experience

McMaster University

Post Doctoral Fellow / September, 2019 — Present

Post-Doctoral Research Fellow / September, 2015 — August, 2016

Universidade Federal de Santa Catarina

Associate professor / October, 2013 — April, 2022

Assistant Professor / October, 2010 — September, 2013

Universidade Federal do Paraná

Post-Doctoral Fellow / December, 2009 — September, 2010

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (6+)

97 total publications

Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats?

Nutrition and Cancer / Sep 21, 2016

Schiessel, D. L., Yamazaki, R. K., Kryczyk, M., Coelho de Castro, I., Yamaguchi, A. A., Pequito, D. C. T., Brito, G. A. P., Borghetti, G., Aikawa, J., Nunes, E. A., Naliwaiko, K., & Fernandes, L. C. (2016). Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats? Nutrition and Cancer, 68(8), 1369–1380. https://doi.org/10.1080/01635581.2016.1224364

Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer

Nutrition and Cancer / Dec 23, 2015

Camargo, C. de Q., Mocellin, M. C., Pastore Silva, J. de A., Fabre, M. E. de S., Nunes, E. A., & Trindade, E. B. S. de M. (2015). Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutrition and Cancer, 68(1), 70–76. https://doi.org/10.1080/01635581.2016.1115097

Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status

Nutrition and Cancer / Feb 24, 2015

Camargo, C. de Q., Borges, D. da S., Oliveira, P. F. de, Chagas, T. R., Del Moral, J. A. G., Durigon, G. S., Dias, B. V., Vieira, A. G., Gaspareto, P., Trindade, E. B. S. de M., & Nunes, E. A. (2015). Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutrition and Cancer, 67(3), 463–471. https://doi.org/10.1080/01635581.2015.1004732

Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats

Journal of Cancer Science &amp; Therapy / Jan 01, 2014

Bordignon, J. (2014). Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats. Journal of Cancer Science &amp; Therapy, 06(03). https://doi.org/10.4172/1948-5956.1000254

Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats

Nutrition and Cancer / Feb 01, 2012

Kuczera, D., Paro de Oliveira, H. H., Fonseca Guimarães, F. de S., de Lima, C., Alves, L., Machado, A. F., Coelho, I., Yamaguchi, A., Donatti, L., Naliwaiko, K., Fernandes, L. C., & Nunes, E. A. (2012). Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats. Nutrition and Cancer, 64(2), 286–293. https://doi.org/10.1080/01635581.2012.647229

Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats

Nutrition and Cancer / Nov 01, 2005

Pizato, N., Bonatto, S., Yamazaki, R. K., Aikawa, J., Nogata, C., Mund, R. C., Nunes, E. A., Piconcelli, M., Naliwaiko, K., Curi, R., Calder, P. C., & Fernandes, L. C. (2005). Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 53(2), 194–201. https://doi.org/10.1207/s15327914nc5302_8

See Full Profile

Dr. Shilpa Patil, Ph.D

Vancouver, British Columbia, Canada
10 Years Experience
PhD & Postdoc level expertise in Cancer Research
Education

University of Göttingen

Ph.D, Cancer Research / June, 2020

Göttingen

Manipal Academy of Higher Education

MSc, Regenerative Medicine / August, 2014

Manipal

Manipal Academy of Higher Education

BSc, Biotechnology / August, 2012

Manipal
Experience

University of British Columbia

Postdoctoral Research Fellow / January, 2021 — July, 2023

University of Gottingen

Postdoctoral Researcher / July, 2020 — December, 2020

JNCASR

Research Assistant / September, 2014 — February, 2016

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (11)
Cancer
epigenetics
development
Oncology
Biophysics
And 6 more
About
Dr. Shilpa Patil is a highly experienced cancer researcher with a strong background in Preclinical studies. She received her Ph.D. in Molecular Medicine from the University of Göttingen in 2020, where she focused on developing novel treatments for pancreatic cancer. Prior to that, she completed her MSc in Regenerative Medicine from Manipal University in 2014 and her BSc in Biotechnology from the same institution in 2012. With over 6 years of research experience, Dr. Patil has worked at prestigious institutions such as the University of British Columbia, University of Göttingen and JNCASR. Her expertise lies in the areas of cancer biology, epigenetics, cell and molecular biology, and regenerative medicine. She has published numerous research articles in reputed journals and has presented her work at various international conferences. Dr. Patil is a dedicated and passionate scientist, committed to using her knowledge and skills to contribute to the fight against cancer. She is driven by her curiosity to unravel complex biological processes and her desire to make a positive impact in the field of cancer research. She is also driven to bridge the academia-industry gap.
Most Relevant Publications (3+)

20 total publications

EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6

Cancer Research / Nov 01, 2020

Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., Versemann, L., Bösherz, M. S., Brunner, M., Gaedcke, J., Ströbel, P., Zhang, J.-S., Neesse, A., Ellenrieder, V., Singh, S. K., … Hessmann, E. (2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Research, 80(21), 4620–4632. https://doi.org/10.1158/0008-5472.can-20-0672

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer

Cancers / Jul 15, 2022

Versemann, L., Patil, S., Steuber, B., Zhang, Z., Kopp, W., Krawczyk, H. E., Kaulfuß, S., Wollnik, B., Ströbel, P., Neesse, A., Singh, S. K., Ellenrieder, V., & Hessmann, E. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers, 14(14), 3451. https://doi.org/10.3390/cancers14143451

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

Cancers / Dec 07, 2021

Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Hessmann, E., & Dobbelstein, M. (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 13(24), 6163. https://doi.org/10.3390/cancers13246163

See Full Profile

Boris Leibovitch

New York, New York, United States of America
30 Years Experience
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Education

Moscow Region State University

PhD, Molecular Biology / April, 1978

Moscow

Moscow Region State University

MS, Genetics / July, 1972

Moscow

Moscow Region State University

BS, Genetics / April, 1971

Moscow
Experience

NYU Langone Medical Center

Associate Research Scientist / June, 2021 — September, 2022

Wet lab research and teaching Molecular and Cell Biology in MD program

Icahn School of Medicine at Mount Sinai

Assistant Professor / July, 2004 — June, 2021

Wet lab research and teaching Molecular and Cell Biology in MD program

Washington University in St. Louis

Post-doctoral Research Associate / June, 1994 — June, 2004

Wet lab research and teaching Molecular and Cell Biology in MS program

Most Relevant Research Expertise
Cancer Research
Other Research Expertise (8)
Cell Biology
Developmental Biology
Molecular Biology
Hematology
Immunology
And 3 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (2+)

22 total publications

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

See Full Profile

Example Cancer Research projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Cancer Research?

Development of Targeted Therapies

An academic researcher in Cancer Research can collaborate with a pharmaceutical company to develop targeted therapies for specific types of cancer. By leveraging their expertise in molecular biology and drug discovery, the researcher can contribute to the design and optimization of novel drugs that selectively target cancer cells while minimizing side effects.

Identification of Novel Biomarkers

A company specializing in diagnostic tools can collaborate with a Cancer Research expert to identify novel biomarkers for early cancer detection. The researcher can utilize their knowledge of cancer biology and molecular techniques to identify specific biomarkers that can be incorporated into diagnostic tests, enabling early intervention and improved patient outcomes.

Genomic Analysis for Personalized Medicine

By partnering with an academic researcher in Cancer Research, a biotech company can leverage genomic analysis to develop personalized medicine approaches. The researcher can analyze genomic data from patients to identify genetic mutations and variations that can inform treatment decisions, leading to more targeted and effective therapies.

Development of Immunotherapies

Collaboration between a pharmaceutical company and a Cancer Research expert can lead to the development of innovative immunotherapies. The researcher can contribute their knowledge of the immune system and cancer immunology to design and optimize immunotherapeutic approaches, enhancing the company's portfolio of cancer treatments.

Exploration of Combination Therapies

An academic researcher in Cancer Research can collaborate with a company to explore combination therapies for cancer treatment. By combining different drugs or treatment modalities, the researcher can help identify synergistic effects and optimize treatment regimens, potentially improving patient outcomes and expanding the company's treatment options.